Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Earnings of -$0.16 Per Share

Wall Street brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.12). Pieris Pharmaceuticals posted earnings of $0.17 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 194.1%. The firm is scheduled to announce its next quarterly earnings results on Friday, March 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.45) per share for the current financial year, with EPS estimates ranging from ($0.49) to ($0.41). For the next financial year, analysts forecast that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.07) to ($0.62). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The firm had revenue of $8.35 million for the quarter, compared to the consensus estimate of $6.16 million.

Several research analysts recently weighed in on PIRS shares. HC Wainwright set a $12.00 price objective on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Sunday, November 11th. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.00.

In related news, Director Christopher P. Kiritsy acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $51,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.07% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP increased its position in shares of Pieris Pharmaceuticals by 589.9% in the third quarter. Marshall Wace LLP now owns 161,078 shares of the biotechnology company’s stock worth $902,000 after purchasing an additional 137,730 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pieris Pharmaceuticals by 13.6% in the third quarter. Vanguard Group Inc. now owns 370,616 shares of the biotechnology company’s stock worth $2,076,000 after purchasing an additional 44,335 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Pieris Pharmaceuticals by 18.6% in the third quarter. TIAA CREF Investment Management LLC now owns 334,082 shares of the biotechnology company’s stock worth $1,871,000 after purchasing an additional 52,302 shares during the last quarter. Platinum Investment Management Ltd. increased its position in shares of Pieris Pharmaceuticals by 54.7% in the third quarter. Platinum Investment Management Ltd. now owns 192,100 shares of the biotechnology company’s stock worth $1,076,000 after purchasing an additional 67,900 shares during the last quarter. Finally, Prosight Management LP increased its position in shares of Pieris Pharmaceuticals by 22.2% in the third quarter. Prosight Management LP now owns 1,661,940 shares of the biotechnology company’s stock worth $9,307,000 after purchasing an additional 301,940 shares during the last quarter. Institutional investors own 65.36% of the company’s stock.

Shares of Pieris Pharmaceuticals stock remained flat at $$3.51 on Monday. 428,334 shares of the stock were exchanged, compared to its average volume of 569,235. Pieris Pharmaceuticals has a 52-week low of $3.04 and a 52-week high of $9.75. The stock has a market capitalization of $190.07 million, a P/E ratio of -8.78 and a beta of 1.88.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit